Polypeptide structural motifs associated with cell signaling activity

Abstract

Isolated polypeptides comprising or consisting essentially of specific structural motifs (e.g., three β-sheets and two α-helices) are provided, wherein the polypeptides exhibit at least one cell signaling and/or other non-canonical activity of biological relevance. Also provided are polynucleotides encoding such polypeptides, binding agents that bind such polypeptides, analogs, variants and fragments of such polypeptides, etc., as well as compositions and methods of identifying and using any of the foregoing.

1 - 35 . (canceled) 
     
     
         36 . A therapeutic composition, comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that specifically binds to a histidyl-tRNA synthetase (HisRS) polypeptide at residues 294-372 of SEQ ID NO: 3, wherein the antibody or antigen-binding fragment thereof is at least about 90% pure. 
     
     
         37 . The therapeutic composition of  claim 36 , wherein the HRS polypeptide consists essentially of three antiparallel β-sheets flanked at each end by an α-helix. 
     
     
         38 . The therapeutic composition of  claim 36 , wherein the antibody or antigen-binding fragment thereof is at least about 95% pure. 
     
     
         39 . The therapeutic composition of  claim 36 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody. 
     
     
         40 . The therapeutic composition of  claim 36 , wherein the antibody is a humanized antibody. 
     
     
         41 . The therapeutic composition of  claim 36 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide. 
     
     
         42 . The therapeutic composition of  claim 36 , which is a sterile, freeze-dried powder. 
     
     
         43 . The therapeutic composition of  claim 36 , which is a sterile injectable solution. 
     
     
         44 . The therapeutic composition of  claim 36 , wherein the composition is buffered and comprises an isotonic agent. 
     
     
         45 . The therapeutic composition of  claim 36 , which is suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration. 
     
     
         46 . The therapeutic composition of  claim 36 , comprising a surfactant.